Moderna announces that its vaccine has a strong efficacy in children aged 6 to 11 years

The American pharmaceutical company Moderna announced on Monday positive results of its vaccine against COVID-19 in children between 6 and 11 years old, and plans to submit the data “in the short term” to regulatory bodies around the world for approval.

Data from clinical trials conducted in more than 4,700 children in this age group show a “strong” immune response in terms of antibody levels and a “favorable safety profile,” Moderna said in a statement.

Information in development …

• AY4.2 | The WHO already monitors the new lineage of the Delta variant detected in the United Kingdom
• COVID-19 | Coronavirus is best transmitted with low temperatures and humidity, according to study
• PAHO seeks to develop test that simultaneously detects COVID-19 and flu
• Study classifies COVID-19 as a seasonal low-temperature infection
• COVID-19 | Pharmaceutical companies and rich countries send only a seventh of promised vaccines to poor countries
• COVID-19 | Pfizer’s vaccine is 93% effective in adolescents
• Delta Plus: the new coronavirus mutation causing a growing number of infections in the UK
• COVID-19 vaccine | Third dose of Pfizer / BioNTech is 95.6% effective
• COVID-19 | FDA approves Moderna and J&J booster doses and combined use of vaccines
• COVID-19: What is known about the combination of Pfizer with the vaccines from Sinopharm, J&J and AstraZeneca?

.

Deshawn